Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02309944 · ClinicalTrials.gov registry record · NA

Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients

A NA study, sponsored by Masonic Cancer Center, University of Minnesota.

Completed
Registry status
NA
Development phase
93
Enrollment target

NCT02309944: Completed NA study, sponsored by Masonic Cancer Center, University of Minnesota.

NCT02309944 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02309944, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.

COMPLETED
Registry status
NA
Development phase
93 participants
Enrollment target

Study Summary

The purpose of the study is to test whether the use of a new wound closure technique can decrease the rates of wound complications in obese cancer patients.

Interventions

  • DEVICE Prevena™ Incision Management System
  • PROCEDURE Standard Wound Closure

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2015-05
Est. Completion 2020-06
Phase NA

What the finished NCT02309944 record still lists

NCT02309944 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Prevena™ Incision Management System is the first listed.

NCT02309944 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02309944 about?

NCT02309944 is a clinical study titled "Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients". The purpose of the study is to test whether the use of a new wound closure technique can decrease the rates of wound complications in obese cancer patients.

What is the current status of trial NCT02309944?

This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2015-05. Estimated completion is 2020-06.

What interventions are being tested in trial NCT02309944?

The interventions under investigation include: Prevena™ Incision Management System (DEVICE), Standard Wound Closure (PROCEDURE).

Who is sponsoring clinical trial NCT02309944?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02309944's enrollment target sits among peer trials

93 937th of 2000 higher than 1,064 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02309944, the US trial registry maintained by the National Library of Medicine. NCT02309944 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.